BioSpace News Archive

Bright Peak Therapeutics, Inc., today announced that it has entered into a license agreement with Livzon Mabpharm, Inc. (“Livzon”), a subsidiary company of Livzon Pharmaceutical Group, to use LZM009, Livzon’s proprietary anti-PD-1 monoclonal antibody currently in late-stage clinical trials, to develop novel PD-1 targeted immunocytokines (“PD-1 ICs”).

The U.S. Food and Drug Administration today authorized marketing of EaseVRx, a prescription-use immersive virtual reality (VR) system that uses cognitive behavioral therapy and other behavioral methods to help with pain reduction in patients 18 years of age and older with diagnosed chronic lower back pain.

DICE Therapeutics, Inc. announced that management will participate in the following investor conferences in November.

Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), today announced the closing of its initial public offering of common stock of 3,520,000 shares at a public offering price of $10.00 per share, for gross proceeds of $35.2 million.

Dante Labs, a global leader in genomics and precision medicine, is pleased to announce its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference.

Cold Spring Harbor Laboratory announces the election of businesswoman and philanthropist Elizabeth Cogan Fascitelli to the private, not-for-profit institution’s board of trustees.

Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will be presenting at the following investor conferences in November.

Alpha Teknova, Inc., a leading provider of critical reagents for the development and production of biopharmaceutical products, including drug therapies, novel vaccines, and molecular diagnostics, announced that the company will participate in the following upcoming investor conferences.

Otsuka America Pharmaceutical, Inc., acknowledges the importance of the favorable opinion of Otsuka’s Hospital Free Trial Program by the Department of Health and Human Services Office of Inspector General, which provides guidance for the design of manufacturer inpatient free trial programs that provide long-acting anti-psychotic injectable products for the treatment of serious mental illness in a hospital setting.

AppliedVR, a pioneer advancing the next generation of immersive therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted de novo approval for its flagship immersive therapeutic, EaseVRx, to treat chronic low back pain, which previously received breakthrough device designation in 2020.